

A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea

NCT07185919

Status RECRUITING
Sponsor Ipsen
Enrollment 10 participants

Key Eligibility Criteria

Inclusion (2)

- Diagnosed with PFIC (all types) who have been prescribed odevixibat (independently of the decision to enrol the participant in this registry) by their treating physician
- On (or starting) active odevixibat treatment Note: Participants can remain in the registry during odevixibat treatment interruptions

Exclusion (3)

- Currently participating in a clinical trial with odevixibat
- Currently participating in any interventional clinical trial for PFIC
- Have any contraindication to odevixibat as per the approved label in South Korea.

Locations (2 total)

Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Yonsei University Health System, Seoul, South Korea